Stephens & Co. Reiterates Overweight on Codexis, Maintains $5 Price Target
Stephens & Co. analyst Steven Etoch reiterates Codexis (NASDAQ:CDXS) with a Overweight and maintains $5 price target.
Follow the latest Codexis, Inc. (CDXS) news and market headlines alongside the live CDXS price. Stay informed on what's moving CDXS.
Stephens & Co. analyst Steven Etoch reiterates Codexis (NASDAQ:CDXS) with a Overweight and maintains $5 price target.
Gainers Cerenome (NASDAQ:CNSY) shares rose 39.5% to $1.07 during Friday's regular session. The market value of their outstanding shares is at $5.8 million. As per the press release, Q3 earnings came out today. SBC
Gainers SELLAS Life Sciences Gr (NASDAQ:SLS) stock rose 19.6% to $9.6 during Friday's pre-market session. The market value of their outstanding shares is at $1.6 billion. As per the news, the Q3 earnings report
Codexis (CDXS) reported a quarterly loss of $0.08 per share, beating consensus estimates of $0.09 loss, with revenues of $19.26 million exceeding expectations by 4.16%. Despite the earnings beat and consistent outperformance over four quarters, the stock has declined 40.1% year-to-date versus the S&P 500's 11.3% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
Codexis (NASDAQ:CDXS) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.10) by 20 percent. This is a 63.64 percent increase over losses of $(0.22) per share from the same
Codexis (NASDAQ:CDXS) affirms FY2026 sales outlook from $72.000 million-$76.000 million to $72.000 million-$76.000 million vs $73.882 million estimate.
News and data on this page is provided by our partnered third-party news and market data provider, with the original publisher credited on each article. All third-party content reflects the views of the original publisher and does not represent the views of MEXC. Price and market data shown on this page are provided by third-party data providers and may be delayed. MEXC offers trading products related to CDXS, including RealStocks and Stock Futures.
The content on this page is provided for informational purposes only and does not constitute investment, financial, or trading advice. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of any news or market data shown. Trading U.S. stocks and related products involves significant risk, and prices can move sharply in a short period. Past performance does not guarantee future results. Please conduct your own research and assess your financial situation and risk tolerance before making any investment decisions. MEXC is not liable for any losses arising from the use of this information.